| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 1/6 |
Green Cross Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩26,900.00 |
| 52 Week High | ₩44,600.00 |
| 52 Week Low | ₩26,050.00 |
| Beta | 0.93 |
| 1 Month Change | 2.48% |
| 3 Month Change | -9.12% |
| 1 Year Change | -17.86% |
| 3 Year Change | -69.26% |
| 5 Year Change | 58.70% |
| Change since IPO | 1,733.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| A005257 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.1% | -1.8% | 0.05% |
| 1Y | -17.9% | 3.4% | 4.5% |
Return vs Industry: A005257 underperformed the KR Biotechs industry which returned 3.4% over the past year.
Return vs Market: A005257 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A005257 volatility | |
|---|---|
| A005257 Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A005257 has not had significant price volatility in the past 3 months.
Volatility Over Time: A005257's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 165 | Il-Sup Huh | www.gcbiopharma.com |
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; and small molecules for gangliosidosis andalagille’s syndrome.
Green Cross Holdings Corporation Fundamentals Summary
| A005257 fundamental statistics | |
|---|---|
| Market cap | ₩649.57b |
| Earnings (TTM) | -₩68.58b |
| Revenue (TTM) | ₩2.09t |
0.3x
P/S Ratio-9.4x
P/E RatioIs A005257 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A005257 income statement (TTM) | |
|---|---|
| Revenue | ₩2.09t |
| Cost of Revenue | ₩1.50t |
| Gross Profit | ₩594.19b |
| Other Expenses | ₩662.77b |
| Earnings | -₩68.58b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51k |
| Gross Margin | 28.44% |
| Net Profit Margin | -3.28% |
| Debt/Equity Ratio | 74.4% |
How did A005257 perform over the long term?
See historical performance and comparison